Glucocorticoids stimulate growth of human papillomavirus type 16 (HPV16)-immortalized human keratinocytes and support HPV16-mediated immortalization without affecting the levels of HPV16 E6/E7 mRNA.

We investigated the effects of the glucocorticoids hydrocortisone and dexamethasone on human papillomavirus type 16 (HPV16)-mediated human cell carcinogenesis using normal human keratinocytes (HKc) and HKc immortalized by transfection with HPV16 DNA (HKc/HPV16). Normal HKc did not require glucocorticoids for proliferation. In contrast, growth of early passage HKc/HPV16 strictly required these hormones, although glucocorticoid dependence became less stringent during in vitro progression. Glucocorticoid dependence was acquired by HKc early after immortalization with HPV16 DNA, and glucocorticoids were required for efficient HKc immortalization. However, treatment of HKc/HPV16 with hydrocortisone or dexamethasone did not increase the steady-state levels of HPV16 E6/E7 mRNA or protein. Firefly luciferase activity expressed under the control of the HPV16 upstream regulatory region and P97 promoter increased by about fourfold following dexamethasone treatment of HeLa, but only twofold in HKc/HPV16, and less than twofold in SiHa. However, all of these cell lines expressed sufficient endogenous glucocorticoid receptors to allow for a dexamethasone response of the mouse mammary tumor virus promoter. These results indicate that mechanisms other than a direct influence by glucocorticoids on HPV16 early gene expression may contribute to the striking biological effects of these steroids on HPV16-mediated human cell carcinogenesis.

[1]  A. C. Maiyar,et al.  Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. , 1997, Molecular endocrinology.

[2]  A. C. Maiyar,et al.  Glucocorticoid-stimulated CCAAT/enhancer-binding protein alpha expression is required for steroid-induced G1 cell cycle arrest of minimal-deviation rat hepatoma cells , 1996, Molecular and cellular biology.

[3]  M. Glade.  Diet and cancer: Molecular mechanisms of interactions , 1996 .

[4]  E. Androphy,et al.  Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. , 1995, Science.

[5]  D. Hanahan,et al.  A transition in transcriptional activation by the glucocorticoid and retinoic acid receptors at the tumor stage of dermal fibrosarcoma development. , 1995, The EMBO journal.

[6]  A. Batova,et al.  Increased levels and constitutive tyrosine phosphorylation of the epidermal growth factor receptor contribute to autonomous growth of human papillomavirus type 16 immortalized human keratinocytes. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  H. Bernard,et al.  Transcriptional control and cell type specificity of HPV gene expression. , 1994, Archives of dermatology.

[8]  M. M. Pater,et al.  Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression, and DNA-protein interactions , 1993, Journal of virology.

[9]  W. Tolleson,et al.  Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons , 1993, Journal of virology.

[10]  K. Münger,et al.  The human papillomavirus E7 protein as a transforming and transactivating factor. , 1993, Biochimica et biophysica acta.

[11]  W. Tolleson,et al.  Retinoic acid inhibition of human papillomavirus type 16-mediated transformation of human keratinocytes. , 1993, Cancer research.

[12]  M. Scheffner,et al.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. , 1991, The EMBO journal.

[13]  M. M. Pater,et al.  RU486 inhibits glucocorticoid hormone-dependent oncogenesis by human papillomavirus type 16 DNA. , 1991, Virology.

[14]  X. Sastre,et al.  Estrogen and progesterone receptors in cervical human papillomavirus related lesions , 1991, International journal of cancer.

[15]  M. von Knebel Doeberitz,et al.  Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  H. Bernard,et al.  Transcriptional activation of human papillomavirus 16 by nuclear factor I, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. , 1990, Nucleic acids research.

[17]  J. Rhim,et al.  Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type 16 and an activated ras oncogene. , 1989, Virology.

[18]  H. Bernard,et al.  Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia , 1989, Journal of virology.

[19]  T. Crook,et al.  Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Nakshatri,et al.  Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA , 1988, Nature.

[21]  R. Schlegel,et al.  Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. , 1988, The EMBO journal.

[22]  J. DiPaolo,et al.  Continuous cell lines with altered growth and differentiation properties originate after transfection of human keratinocytes with human papillomavirus type 16 DNA. , 1988, Carcinogenesis.

[23]  M. von Knebel Doeberitz,et al.  Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. , 1988, Cancer research.

[24]  S. Nordeen,et al.  Luciferase reporter gene vectors for analysis of promoters and enhancers. , 1988, BioTechniques.

[25]  L. Turek,et al.  Transcriptional regulation of the human papillomavirus‐16 E6‐E7 promoter by a keratinocyte‐dependent enhancer, and by viral E2 trans‐activator and repressor gene products: implications for cervical carcinogenesis. , 1987, The EMBO journal.

[26]  B. Gloss,et al.  The upstream regulatory region of the human papilloma virus‐16 contains an E2 protein‐independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. , 1987, The EMBO journal.

[27]  L. Gissmann,et al.  Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women , 1987, International journal of cancer.

[28]  J. DiPaolo,et al.  Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA , 1987, Journal of virology.

[29]  D. Savitz,et al.  Long‐term use of oral contraceptives and risk of invasive cervical cancer , 1986, International journal of cancer.

[30]  W. Pratt,et al.  Inactivation of glucocorticoid-binding capacity by protein phosphatases in the presence of molybdate and complete reactivation of dithiothreitol. , 1982, The Journal of biological chemistry.

[31]  A. Batova,et al.  Increased sensitivity of human keratinocytes immortalized by human papillomavirus type 16 DNA to growth control by retinoids. , 1992, Cancer research.

[32]  E. Lees,et al.  Transformation of primary BRK cells by human papillomavirus type 16 and EJ-ras is increased by overexpression of the viral E2 protein. , 1990, The Journal of general virology.